Literature DB >> 20484430

1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery.

Ren-Shyan Liu1, Chen-Pei Chang, Wen-You Guo, David H C Pan, Donald Ming-Tak Ho, Chi-Wei Chang, Bang-Hung Yang, Liang-Chi Wu, Shin-Hwa Yeh.   

Abstract

UNLABELLED: This study aimed to define the potential of 1-(11)C-acetate PET, compared with (18)F-FDG, in detecting meningiomas and monitoring the effect of gamma-knife radiosurgery.
METHODS: Twenty-two patients with the neuroradiologic diagnosis of meningioma were examined by 1-(11)C-acetate and (18)F-FDG PET on the same day. There were 12 cases of histopathologically proven meningioma (8 grade I, 2 grade II, and 2 grade III), 1 of tuberculous granuloma, and 1 of degenerative tissue. 1-(11)C-acetate PET scans of fasting patients were obtained 10 min after intravenous administration of 740 MBq of 1-(11)C-acetate. (18)F-FDG PET was performed at 2 h after 1-(11)C-acetate scanning. The PET images were evaluated by a qualitative method and semiquantitative analysis using standardized uptake value and tumor-to-cortex ratio.
RESULTS: The (18)F-FDG PET study revealed a hypometabolic focus in 17 meningiomas (8 grade I, 1 grade II, and 8 unknown grade) and hypermetabolism in 1 grade II and 2 grade III meningiomas. High uptake of 1-(11)C-acetate was observed in all 20 meningiomas, in contrast to the low uptake in surrounding normal brain tissue, allowing a clearer demarcation of the tumor boundary than that provided by (18)F-FDG. Dissociation of regional accumulation of 1-(11)C-acetate and (18)F-FDG within the tumor was also noted on the coregistered images. The standardized uptake value for 1-(11)C-acetate was not different from that for (18)F-FDG (mean +/- SD, 3.16 +/- 1.75 vs. 3.22 +/- 1.50, P = 0.601), but the tumor-to-cortex ratio for 1-(11)C-acetate was higher than that for (18)F-FDG (3.46 +/- 1.38 vs. 0.93 +/- 1.08, P < 0.005). (18)F-FDG was able to differentiate grade I from grade II-III meningiomas, whereas 1-(11)C-acetate was unable to do so. Tuberculous granuloma had a high 1-(11)C-acetate and (18)F-FDG uptake similar to that of grade II/III meningioma. Five patients received 1-(11)C-acetate and (18)F-FDG PET before and after gamma-knife surgery. 1-(11)C-acetate performed better than did (18)F-FDG in monitoring the response of tumor metabolism to radiosurgery.
CONCLUSION: 1-(11)C-acetate was found to be useful for detecting meningiomas and evaluating the extent of meningiomas and potentially useful for monitoring tumor response to radiosurgery. However, 1-(11)C-acetate was not useful for evaluating the tumor grade. (18)F-FDG was found to be less useful than 1-(11)C-acetate for evaluating the extent of meningiomas and the response to radiosurgical treatment but may be useful for differentiating benign from malignant meningiomas. (18)F-FDG and 1-(11)C-acetate are complementary for assessing diverse cell metabolism of meningioma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484430     DOI: 10.2967/jnumed.109.070565

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results.

Authors:  Jan F Cornelius; Gabriele Stoffels; Christian Filß; Norbert Galldiks; Philipp Slotty; Marcel Kamp; Mustafa el Khatib; Daniel Hänggi; Michael Sabel; Jörg Felsberg; Hans Jakob Steiger; Heinz H Coenen; Nadim J Shah; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

Review 2.  Current molecular imaging of spinal tumors in clinical practice.

Authors:  Nora Sandu; Gabriele Pöpperl; Marie-Elisabeth Toubert; Toma Spiriev; Belachew Arasho; Mikael Orabi; Bernhard Schaller
Journal:  Mol Med       Date:  2011-01-03       Impact factor: 6.354

Review 3.  PET imaging in patients with meningioma-report of the RANO/PET Group.

Authors:  Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

Review 4.  Exploiting metabolic differences in glioma therapy.

Authors:  Francesca Galeffi; Dennis A Turner
Journal:  Curr Drug Discov Technol       Date:  2012-12

5.  Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a systematic literature review.

Authors:  Hong-Da Zhu; Qing Xie; Ye Gong; Ying Mao; Ping Zhong; Feng-Ping Hang; Hong Chen; Ming-Zhe Zheng; Hai-Liang Tang; Dai-Jun Wang; Xian-Cheng Chen; Liang-Fu Zhou
Journal:  Int J Clin Exp Med       Date:  2013-08-01

6.  The clinical use of PET with (11)C-acetate.

Authors:  Ilaria Grassi; Cristina Nanni; Vincenzo Allegri; Joshua James Morigi; Gian Carlo Montini; Paolo Castellucci; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

7.  SPECT and PET imaging of meningiomas.

Authors:  Varvara Valotassiou; Anastasia Leondi; George Angelidis; Dimitrios Psimadas; Panagiotis Georgoulias
Journal:  ScientificWorldJournal       Date:  2012-05-01

8.  Cluster-Like Headache Secondary to Anamnesis of Sphenoid Ridge Meningioma: A Case Report and Literature Review.

Authors:  Liang Kou; Jinsha Huang; Yan Xu; Chao Han; Kai Ma; Xingfang Guo; Yun Xia; Fang Wan; Sijia Yin; Junjie Hu; Jiawei Wu; Yadi Sun; Guoxin Zhang; Ling Liu; Nian Xiong; Tao Wang
Journal:  Front Neurol       Date:  2019-01-25       Impact factor: 4.003

9.  Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer.

Authors:  Marina Hodolic; Virginie Huchet; Sona Balogova; Laure Michaud; Khaldoun Kerrou; Valérie Nataf; Marino Cimitan; Jure Fettich; Jean-Noël Talbot
Journal:  Radiol Oncol       Date:  2014-07-10       Impact factor: 2.991

Review 10.  Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.

Authors:  Amarnath Challapalli; Eric O Aboagye
Journal:  Front Oncol       Date:  2016-02-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.